Global Allergic Rhinitis Drugs Market 2017-2027

アレルギー性鼻炎治療薬の世界市場

◆タイトル:Global Allergic Rhinitis Drugs Market 2017-2027
◆商品コード:VGAIN7081174
◆調査・発行会社:visiongain
◆発行日:2017年5月
◆ページ数:255
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Sigle User(1名閲覧)GBP2,499 ⇒換算¥374,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

visiongain社が発行した当調査レポートでは、アレルギー性鼻炎治療薬の世界市場について調査・分析し、アレルギー性鼻炎治療薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・イントロダクション
・アレルギー性鼻炎治療薬の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・アレルギー性鼻炎治療薬の世界市場:セグメント別市場分析
・アレルギー性鼻炎治療薬の世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

The global allergic rhinitis drugs market is expected to grow at a CAGR of 3.2% in the first half of the forecast period. The market is expected to grow at a CAGR of 3.3% from 2016-2027. The market is estimated at $11.9bn in 2016 and $13.9bn in 2021.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 255-page report you will receive 85 tables and 88 figures – all unavailable elsewhere.

The 255-page report provides clear detailed insight into the global allergic rhinitis drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Global Allergic Rhinitis Drugs Market forecasts from 2017-2027

• Along with revenue prediction for the overall world market for allergic rhinitis drugs, our investigation shows forecasts to 2027 for the following submarkets:
- Intranasal Antihistamines
- Intranasal Corticosteroids
- Oral Antihistamines
- Immunotherapy and Vaccines

• How will leading allergic rhinitis drugs perform to 2027 at world level? Our study forecasts individual revenues of these 27 products:
- Patanase
- Astepro
- Astelin
- Dymista
- Nasonex
- Avamys
- Veramyst
- Flixonase
- Rhinocort
- Omnaris
- Nasacort
- Beconase
- Qnasl
- Zetonna
- Allegra
- Zyrtec
- Claritin
- Xyzal
- Allelock
- Clarinex
- Ebastel
- Talion
- Staloral
- Alutard SQ
- Grazax
- Ragwitek
- Generic Azelastine

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
- US
- EU5 – Germany, UK, France, Italy and Spain
- China
- Japan
- India
- Russia
- Brazil
- Rest of the World

• Our work provides analysis and sales forecast of the leading companies in the allergic rhinitis drugs market:
- GlaxoSmithKline (GSK)
- Merck & Co
- Sanofi
- Johnson & Johnson
- ALK-Abello
- UCB
- Kyowo Hako Kirin
- Stallergenes Greer

• This report discusses the trends and development in the allergic rhinitis pipeline

• Our study discusses strengths, weaknesses, opportunities and threats as well as porter’s five forces analysis of the global allergic rhinitis drugs market

Visiongain’s study is intended for anyone requiring commercial analyses for the global allergic rhinitis drugs market. You find data, trends and predictions.

Buy our report today Global Allergic Rhinitis Drugs Market 2017-2027: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines.

【レポートの目次】

1. Report Overview
1.1 Global Allergic Rhinitis Drugs: Market Overview
1.2 Global Allergic Rhinitis Drugs Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain

2. An Introduction to Allergic Rhinitis Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Allergic Rhinitis Treatments – An Industry Overview
2.2 A Brief Overview of Allergy
2.3 Allergic Rhinitis
2.3.1 The Global Prevalence of Allergic Rhinitis
2.3.2 Pathophysiology of Allergic Rhinitis: IgEs and Mast Cells
2.3.3 Symptoms of Allergic Rhinitis
2.3.4 Classification of Allergic Rhinitis
2.3.4.1 Non-Allergic Rhinitis and Mixed Rhinitis
2.3.5 Seasonal Allergic Rhinitis (Hay Fever)
2.3.6 Perennial Allergic Rhinitis
2.3.7 Diagnosis of Allergic Rhinitis
2.4 Treatment of Allergic Rhinitis
2.4.1 Antihistamines
2.4.1.1 First-Generation Antihistamines
2.4.1.2 Second- and Third-Generation Antihistamines
2.4.2 Corticosteroids
2.4.2.1 First-, Second- and Third-Generation Intranasal Corticosteroids
2.4.2.2 Combination Drug Products
2.4.3 Leukotriene Receptor Antagonists
2.4.4 Cromolyn (cromoglicic acid)
2.4.5 Decongestants
2.4.6 Saline Nasal Sprays
2.4.7 Immunotherapy and Vaccines
2.5 Phases of Clinical Trials
2.6 Scope of this Report

3. The Global Allergic Rhinitis Drugs Market, 2017-2027
3.1 The Global Allergic Rhinitis Drugs Market: Market Overview
3.2 Categorisation of The Global Allergic Rhinitis Drugs Market
3.3 The Global Allergic Rhinitis Drugs Market in 2016
3.4 The Global Allergic Rhinitis Drugs Market: Market Forecast 2017-2027
3.5 Allergic Rhinitis Drugs: Changing Market Shares by Sector 2017-2027

4. Oral Antihistamines Market: Market Analysis and Forecast 2017-2027
4.1 Oral Antihistamines: Market Overview
4.1.1 Leading Products in the Oral Antihistamines Market, 2016
4.2 Oral Antihistamines: Market Trends and Developments, 2017
4.2.1 Patent Expiries and the Threat of Generics
4.2.2 The Increasing Switch from Prescription to Over-The-Counter Sales
4.2.3 The Potential for Combination Therapy with Intranasal Corticosteroids
4.3 Oral Antihistamines: Market Forecast 2017-2027
4.3.1 Oral Antihistamines: Changing Market Shares by Leading Drugs 2017-2027
4.4 Leading Oral Antihistamines for the Treatment of Allergic Rhinitis
4.4.1 Allegra/Allegra-D/Allegra OTC (fexofenadine) – Sanofi
4.4.1.1 Allegra/Allegra OTC: Historical Sales, 1995-2014
4.4.1.2 Allegra/Allegra OTC: Sales Forecast 2016-2027
4.4.2 Claritin/Claritin OTC (loratadine) – Bayer/ Merck & Co
4.4.2.1 Claritin/Claritin OTC: Sales Forecast 2017-2027
4.4.3 Zyrtec/Zyrtec D (cetirizine) – Johnson & Johnson/ UCB/ GSK
4.4.3.1 Zyrtec/Zyrtec D: Sales Forecast 2017-2027
4.4.4 Xyzal (levocetirizine) – Sanofi/ UCB/ GSK
4.4.4.1 Xyzal: Sales Forecast 2017-2027
4.4.5 Clarinex (desloratadine) – Merck & Co.
4.4.5.1 Clarinex: Sales Forecast 2017-2027
4.4.6 Allelock (olopatadine) – Kyowa Hakko Kirin
4.4.6.1 Allelock: Sales Forecast 2017-2027
4.4.7 Ebastel (ebastine) – AstraZeneca/Takeda/Dainippon Sumitomo
4.4.7.1 Ebastel: Sales Forecast 2017-2027
4.4.8 Talion (bepotastine) – Mitsubishi Tanabe
4.4.8.1 Talion: Sales Forecast 2017-2027
4.4.9 Other Oral Antihistamines: Sales Forecast 2017-2027

5. Intranasal Corticosteroids Market: Market Analysis and Forecast 2017-2027
5.1 Leading Products in the Intranasal Corticosteroids Market, 2016
5.2 Intranasal Corticosteroids: Market Forecast 2017-2027
5.2.1 Intranasal Corticosteroids: Changing Market Shares by Leading Drugs 2017-2027
5.3 Leading Intranasal Corticosteroids
5.3.1 Flixonase/Flonase/Flonase-OTC (fluticasone propionate) – GlaxoSmithKline
5.3.1.1 Flixonase/Flonase/Flonase-OTC Forecast, 2017-2027
5.3.2 Nasonex (mometasone) – Merck
5.3.2.1 Nasonex Forecast, 2017-2027
5.3.3 Avamys/Veramyst (fluticasone furoate) – GlaxoSmithKline
5.3.3.1 Avamys/Veramyst Forecast, 2017-2027
5.3.4 Rhinocort (budesonide) – AstraZeneca
5.3.4.1 Rhinocort Forecast, 2017-2027
5.3.5 Nasacort/Nasacort-OTC (triamcinolone) – Sanofi
5.3.5.1 Nasacort/Nasacort-OTC Forecast, 2017-2027
5.3.6 Omnaris (ciclesonide) – Dainippon Sumitomo/Takeda
5.3.6.1 Omnaris: Sales Forecast, 2017-2027
5.3.7 Beconase/Beconase AQ (beclometasone) – GlaxoSmithKline/Omega Pharma
5.3.7.1 Beconase/Beconase AQ Forecast, 2017-2027
5.3.8 Qnasl (beclometasone) – Teva
5.3.8.1 Qnas Forecast, 2017-2027
5.3.9 Zetonna (ciclesonide) – Dainippon Sumitomo
5.3.9.1 Zetonna Forecast, 2017-2027

6. Immunotherapy and Vaccines: Market Analysis and Forecast 2017-2027
6.1 Immunotherapy and Vaccines: Market Overview
6.1.1 Immunotherapy: Primed for Rapid Expansion
6.2 Leading Immunotherapy Products in the Allergic Rhinitis Market, 2016
6.3 Allergic Rhinitis Immunotherapy: Market Trends and Developments, 2016
6.3.1 Subcutaneous and Sublingual Immunotherapy
6.3.2 Expansion into the US Market
6.3.3 Standardisation of Immunotherapy Products
6.3.4 Immunotherapy as a Preventative Treatment
6.4 Allergic Rhinitis Immunotherapy: Market Forecast 2017-2027
6.4.1 Allergic Rhinitis Immunotherapy: Changing Market Shares by Leading Products 2017-2027
6.5 Immunotherapy Type – By Route of Administration, 2016
6.6 Leading Immunotherapy Products for Allergic Rhinitis
6.6.1 Staloral (Grass pollen allergen extract) – Stallergenes
6.6.1.1 Staloral: Sales Forecast 2017-2027
6.6.2 Alutard SQ (Grass pollen allergen extract) – ALK-Abelló
6.6.2.1 Alutard SQ: Sales Forecast 2017-2027
6.6.3 Grazax/Grastek (Timothy grass pollen allergen extract) – ALK-Abelló/Merck
6.6.3.1 Grazax/Grastek: Sales Forecast 2016-2027
6.6.4 Oralair (Grass pollen allergen extract) – Stallergenes/Greer
6.6.4.1 Oralair: Sales Forecast 2017-2027
6.6.5 Ragwitek (Short ragweed pollen allergen extract) – Merck
6.6.5.1 Ragwitek: Sales Forecast 2017-2027
6.6.6 Other Allergic Rhinitis Immunotherapy Products: Sales Forecast 2017-2027

7. The Intranasal Antihistamines Market: Market Analysis and Forecast 2017-2027
7.1 Leading Products in the Intranasal Antihistamines Market, 2016
7.2 Intranasal Antihistamines: Market Trends and Developments, 2017
7.2.1 Azelastine versus Olopatadine
7.2.2 Intranasal Combination Products
7.3 Intranasal Antihistamines: Market Forecast 2017-2027
7.3.1 Intranasal Antihistamines: Changing Market Shares by Leading Drugs 2017-2027
7.4 Leading Intranasal Antihistamines
7.4.1 Dymista (azelastine/fluticasone) – Meda Pharmaceuticals
7.4.1.1 Mylan Acquires Meda Pharmaceuticals
7.4.1.2 Dymista: Sales Forecast 2017-2027
7.4.2 Generic Intranasal Azelastine
7.4.2.1 Generic Intranasal Azelastine: Sales Forecast, 2017-2027
7.4.3 Astepro (azelastine) – Meda Pharmaceuticals
7.4.3.1 Astepro: Sales Forecast 2016-2027
7.4.4 Patanase (olopatadine) – Novartis
7.4.4.1 Patanase: Sales Forecast 2016-2027
7.4.5 Astelin (azelastine) – Meda Pharmaceuticals
7.4.5.1 Astelin: Sales Forecast 2017-2027

8. Leading National Markets for Allergic Rhinitis Drugs, 2016-2027
8.1 The Allergic Rhinitis Drugs Market by Region
8.1.1 The Global Distribution of Allergic Rhinitis Drugs in 2016
8.2 Leading National Markets: Forecast 2016-2027
8.2.1 Changing Market Shares by Region, 2016-2027
8.3 Regional Allergic Rhinitis Drugs Markets: Analysis and Forecasts, 2016-2027
8.3.1 United States: The Largest Allergic Rhinitis Drugs Market
8.3.1.1 US Allergic Rhinitis Drugs Market: Trends and Developments
8.3.1.2 US Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
8.3.2 EU5
8.3.2.1 EU5 Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
8.3.2.2 EU5 Markets: Changing Market Shares by Country, 2016-2027
8.3.2.3 Germany
8.3.2.4 UK
8.3.2.5 France
8.3.2.6 Italy
8.3.2.7 Spain
8.4 China
8.4.1 Air Pollution Associated with Increasing Prevalence
8.4.2 Expansion of Healthcare Coverage and Reimbursement in China
8.4.3 China Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
8.5 Japan
8.5.1 Cedar Reforestation and the Hay Fever Epidemic
8.5.2 Genetically Modified Rice as Immunotherapy
8.5.3 Effects of the Rising Levels of Generic Drug Penetration
8.5.4 Japan Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
8.6 Russia
8.6.1 How Will Russia’s Economic Status Affect Its Pharma Industry?
8.6.2 Russia Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
8.7 India
8.7.1 The Impact of the Drug Prices Control Order on Indian Pharma
8.7.2 India’s Expansion of Healthcare Provision
8.7.3 India Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
8.8 Brazil
8.8.1 How Will Brazil’s Growing Healthcare Influence Allergic Rhinitis Drugs
8.8.2 Brazil Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
8.9 Rest of the World
8.9.1 Rest of the World Allergic Rhinitis Drugs Market: Market Forecast 2016-2027

9. Leading Companies in the Allergic Rhinitis Drugs Market, 2016-2027
9.1 Allergic Rhinitis Drugs – An Evolving Market Space
9.1.1 Leading Companies in the Allergic Rhinitis Drugs Market, 2016
9.2 ALK-Abelló
9.2.1 ALK-Abelló: Allergic Rhinitis Drugs Portfolio, 2017
9.2.2 ALK-Abelló: Recent Developments
9.2.2.1 ALK Acquired Allergy Laboratories, Inc. and Crystal Laboratory LLC to Strengthen Its Supply Chain Activities
9.2.2.2 ACARIZAX Launched in Europe progressing to International Roll-Out
9.2.2.3 ALK Collaborates with EddingPharm to Boost China Sales
9.2.2.4 ALK-Abelló: Sales Forecast 2016-2027
9.2.2.5 ALK-Abelló: Allergic Rhinitis Drug Development Pipeline, 2016
9.3 GlaxoSmithKline (GSK)
9.3.1 GlaxoSmithKline: Allergic Rhinitis Drugs Portfolio, 2017
9.3.2 GlaxoSmithKline: Sales Forecast 2016-2027
9.4 Johnson & Johnson
9.4.1 Johnson & Johnson: Allergic Rhinitis Drugs Portfolio, 2017
9.4.2 Johnson & Johnson: Recent Developments
9.4.2.1 Manufacturing Recalls at McNeil Consumer Healthcare
9.4.2.2 Johnson & Johnson: Sales Forecast 2016-2027
9.5 Kyowa Hakko Kirin
9.5.1 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Portfolio, 2017
9.5.2 Kyowa Hakko Kirin: Sales Forecast 2016-2027
9.6 Merck & Co.
9.6.1 Merck: Allergic Rhinitis Drugs Portfolio, 2017
9.6.2 Merck: Recent Developments
9.6.2.1 Bayer Acquires Merck’s Consumer Health Business
9.6.2.2 FDA Rejects Singulair OTC Switch
9.2.6.3 Merck: Sales Forecast 2016-2027
9.2.6.4 Merck: Allergic Rhinitis Drug Development Pipeline, 2017
9.7 Sanofi
9.7.1 Sanofi: Allergic Rhinitis Drugs Portfolio, 2017
9.7.2 Sanofi: Sales Forecast 2016-2027
9.7.3 Sanofi: Recent Developments
9.7.3.1 Sanofi Received US FDA Approval for Its Xyzal Allergy 24HR
9.8 Stallergenes Greer
9.8.1 Stallergenes: Allergic Rhinitis Drugs portfolio, 2017
9.8.2 Stallergenes Greer: Sales Forecast 2016-2027
9.8.3 Stallergenes Greer: Allergic Rhinitis Drug Development Pipeline, 2017
9.9 UCB
9.9.1 UCB: Allergic Rhinitis Drugs Portfolio, 2017
9.9.2 UCB: Sales Forecast 2016-2027
9.10 Other Leading Companies within the Allergic Rhinitis Drugs Market

10. Allergic Rhinitis Drugs: Research and Development Pipeline, 2016-2027
10.1 Trends and Developments in the Allergic Rhinitis Pipeline
10.2 The R&D Pipeline for Oral Antihistamines, 2017
10.2.1 Talion (bepotastine) – Mitsubishi Tanabe
10.2.2 ZPL-3893787 (histamine H4R antagonist) – Ziarco Pharma
10.3 The R&D Pipeline for Intranasal Corticosteroids, 2017
10.3.1 APC-3000 (HFA inhaled corticosteroid) – Adamis Pharmaceuticals
10.3.2 TBS-6 – Trimel Pharmaceuticals
10.4 The R&D Pipeline for Immunotherapy in Allergic Rhinitis, 2017
10.4.1 Actair (house dust mite SLIT; STG320) – Stallergenes/Shionogi & Co
10.4.2 AllerT (subcutaneous birch pollen immunotherapy) – Anergis
10.4.3 Depigoid Birch 5000 (birch pollen allergen extract, Leti Pharma
10.4.4 House Dust Mite SLIT-Tablet (MK-8237) – ALK-Abelló/Merck/Torii
10.4.5 Pollinex Quattro (subcutaneous immunotherapies) – Allergy Therapeutics
10.4.6 gp-ASIT+ (grass pollen allergen fragments) – Biotech Tools
10.4.7 Betula verrucosa (Bet v) 1 allergen – Stallergenes Greer
10.5 The R&D Pipeline for Other Allergic Rhinitis Drugs
10.5.1 S-555739 (prostaglandin D2 receptor antagonist) – Shionogi
10.5.2 DSP-3025/AZD-8848 (toll-like receptor 7 agonist) – Dainippon Sumitomo/ AstraZeneca
10.5.3 GSK2245035 (toll-like receptor 7 agonist) – GSK
10.5.4 HP-3060 (transdermal long-acting tape) – Hisamitsu
10.5.5 MRX-4 (anti-inflammatory agent) – Celsus Therapeutics

11. Qualitative Analysis of the Allergic Rhinitis Drugs Market, 2016-2027
11.1 Market Factors Influencing Allergic Rhinitis Drugs
11.2 SWOT Analysis of The Global Allergic Rhinitis Drugs Market, 2016-2027
11.2.1 Strengths
11.2.1.1 OTC-Switch Facilitating Ease of Consumer Access
11.2.1.2 The Established Role of Allergic Rhinitis Drugs in Treatment
11.2.1.3 Allergic Rhinitis and Rising Unmet Clinical Need
11.2.1.4 Rising Profile of Allergic Rhinitis in Various Regions Driving Healthcare Provision
11.2.2 Weaknesses
11.2.2.1 Intranasal Corticosteroids and Patients’ Satisfaction Rates
11.2.2.2 Increasing Penetration of Generic Drug Products
11.2.2.3 The Challenge Raised by The Low Volume of Pipeline Developments
11.2.3 Opportunities
11.2.3.1 Growth in Emerging Markets Outstripping Established Markets
11.2.3.2 Rx-to-OTC Switching and The Effects on Revenue Potential
11.2.3.3 Combination Drug Products Providing Rising Efficacy Profiles
11.2.3.4 The Emergence of Immunotherapy in Allergic Rhinitis
11.2.4 Threats
11.2.4.1 Cost-Containment as A Growth Restraint
11.2.4.2 Rising Cost of APIs and Manufacturing
11.2.4.3 Patent Expiries and The Resultant Loss of Revenue
11.3 Porter’s Five Forces Analysis of the Global Allergic Rhinitis Drugs Market, 2016-2027
11.3.1 Power of Buyers
11.3.2 Power of Suppliers
11.3.3 Threat of Substitutes
11.3.4 Threat 0f New Entrants
11.3.5 Rivalry Among Competitors

12. Conclusion
12.1 Overview of Current Market Conditions and Market Forecast, 2016-2027
12.2 Leading Sectors in the Allergic Rhinitis Drugs Market in 2016
12.3 Leading Regions in the Allergic Rhinitis Drugs Market in 2016
12.4 Leading Companies in the Allergic Rhinitis Drugs Market, 2016
12.5 What Does the Future Hold for Allergic Rhinitis Drugs?

Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 1.1 (Sample) Allergic Rhinitis Market Forecast by National Market: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 2.1 Leading Antihistamines for Allergic Rhinitis, 2017
Table 2.2 Leading Corticosteroids for Allergic Rhinitis, 2017
Table 2.3 Clinical Trial Phases
Table 3.1 The Global Allergic Rhinitis Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2016
Table 3.2 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
Table 3.3 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2016, 2021, 2027
Table 4.1 Leading Oral Antihistamines: Revenue ($m) and Market Share (%), 2016
Table 4.2 Oral Antihistamines Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.3 The Global Oral Antihistamines Market: Market Share (%), 2016, 2021, 2027
Table 4.4 Allegra/Allegra-D/Allegra OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.5 Claritin/Claritin OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.6 Zyrtec/Zyrtec-D Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.7 Xyzal Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 4.8 Clarinex Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 4.9 Allelock Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.10 Ebastel Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.11 Talion Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.12 Other Oral Antihistamines Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 5.1 Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m) and Market Shares (%), 2016
Table 5.2 Intranasal Corticosteroids Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 5.3 The Global Intranasal Corticosteroids Market: Market Share (%), 2016, 2021, 2027
Table 5.4 Flixonase/Flonase/Flonase-OTC Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
Table 5.5 Nasonex Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.6 Avamys/Veramyst Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.7 Rhinocort: Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.8 Nasacort/Nasacort-OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.9 Omnaris Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.10 Beconase/Beconase AQ Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.11 Qnasl Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.12 Zetonna Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.1 Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m) and Market Share (%), 2016
Table 6.2 Allergic Rhinitis Immunotherapy Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 6.3 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2016, 2021, 2027
Table 6.4 Allergic Rhinitis Immunotherapy Market by Type: Revenue ($m) and Market Share (%), 2016
Table 6.5 Staloral Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.6 Alutard SQ Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 6.7 Grazax/Grastek Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 6.8 Oralair Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.9 Ragwitek Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.10 Other Allergic Rhinitis Immunotherapy Products Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.1 Top Drugs In The Intranasal Antihistamines Market: Revenue ($m) and Market Shares (%), 2016
Table 7.2 Intranasal Antihistamines Market Forecast by Leading Drugs: Revenue ($m), AGR (%), and CAGR%), 2016-2027
Table 7.3 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2016, 2021, 2027
Table 7.4 Dymista (Meda Pharma) Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.5 Generic Intranasal Azelastine Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.6 Astepro Forecast; Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.7 Patanase Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.8 Astelin Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.1 The Global Allergic Rhinitis Drugs Market by Region: Revenue ($m) and Market Share (%), 2016
Table 8.2 Global Allergic Rhinitis Drugs Market Forecast by Region: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.3 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2016, 2021, and 2027
Table 8.4 US Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.5 The EU5 Allergic Rhinitis Drugs Market Forecast by Country: Revenue ($m) and Market Share (%), 2016
Table 8.6 The EU5 Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 8.7 The EU5 Allergic Rhinitis Drugs Market by Country: Market Share (%), 2016, 2021, 2027
Table 8.8 Germany Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.9 UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.10 France Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
Table 8.11 Italy Allergic Rhinitis Drugs Market Forecat: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
Table 8.12 Spain Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
Table 8.13 China Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 8.14 Japan Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
Table 8.15 Russia Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.16 India Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.17 Brazil Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.18 Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 9.1 Leading Companies in The Allergic Rhinitis Drug Market: Revenues ($m) and Market Shares (%), 2016
Table 9.2 ALK- Abelló: Company Overview, 2017
Table 9.3 ALK-Abelló: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 9.4 GlaxoSmithKline: Company Overview, 2017
Table 9.5 GlaxoSmithKline: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 9.6 Johnson & Johnson: Company Overview, 2017
Table 9.7 Johnson & Johnson Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 9.8 Kyowa Hakko Kirin: Company Overview, 2017
Table 9.9 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 9.10 Merck & Co.: Company Overview, 2017
Table 9.11 Merck & Co: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 9.12 Sanofi: Company Overview, 2017
Table 9.13 Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 9.14 Stallergenes Greer: Company Overview, 2016
Table 9.15 Stallergenes Greer: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 9.16 UCB: Company Overview, 2017
Table 9.17 UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 11.1 SWOT Analysis of the Global Allergic Rhinitis Drugs Market, 2016-2027

List of Figures
Figure 1.1 Global Allergic Rhinitis Drugs Market: Market Sectors, 2017
Figure 2.1 Role of Mast Cells and IgE in Allergic Rhinitis, 2017
Figure 3.1 The Global Allergic Rhinitis Drugs Market: Revenue ($m) by Sector, 2016
Figure 3.2 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%) by Sector, 2016-2027
Figure 3.3 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2016
Figure 3.4 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2021
Figure 3.5 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2027
Figure 4.1 Leading Oral Antihistamines: Revenue ($m), 2016
Figure 4.2 Oral Antihistamines Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.3 The Global Oral Antihistamines Market: Market Share (%), 2016
Figure 4.4 The Global Oral Antihistamines Market: Market Share (%), 2021
Figure 4.5 The Global Oral Antihistamines Market: Market Share (%), 2027
Figure 4.6 Allegra (Allegra Rx and Allegra OTC) Historical Sales: Revenue ($m),1995-2016
Figure 4.7 Allegra/Allegra-D/Allegra OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.8 Claritin/Claritin OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.9 Zyrtec/Zyrtec-D Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.10 Xyzal Forecast: Revenue($m) and AGR (%), 2016-2027
Figure 4.11 Clarinex Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.12 Allelock Forecast: Revenue($m) and AGR (%), 2016-2027
Figure 4.13 Ebastel Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.14 Talion Forecast: Revenue($m) and AGR (%), 2016-2027
Figure 4.15 Other Oral Antihistamines Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.1 Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m), 2016
Figure 5.2 Intranasal Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.3 The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2016
Figure 5.4 The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2021
Figure 5.5 The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2027
Figure 5.6 Flixonase/Flonase/Flonase-OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.7 Nasonex Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.8 Avamys/Veramyst Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.9 Rhinocort Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.10 Nasacort/Nasacort-OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.11 Omnaris Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.12 Beconase/Beconase AQ Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.13 Qnasl Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.14 Zetonna Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.1 Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m), 2016
Figure 6.2 Allergic Rhinitis Immunotherapy Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.3 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2016
Figure 6.4 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2021
Figure 6.5 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2027
Figure 6.6 Allergic Rhinitis Immunotherapy Market: Market Share (%) by Immunotherapy Type, 2016
Figure 6.7 Staloral Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.8 Alutard SQ Forecast: Revenue($m) and AGR (%), 2016-2027
Figure 6.9 Grazax/Grastek Forecast: Revenue($m) and AGR (%), 2016-2027
Figure 6.10 Oralair Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.11 Ragwitek Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.12 Other Allergic Rhinitis Immunotherapy Products Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 7.1 Top Drugs in The Intranasal Antihistamines Market: Revenue ($m), 2016
Figure 7.2 Intranasal Antihistamines Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 7.3 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2016
Figure 7.4 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2021
Figure 7.5 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2027
Figure 7.6 Dymista (Meda Pharma) Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 7.7 Generic Intranasal Azelastine Forecast: Revenue ($m) and, AGR (%), 2016-2027
Figure 7.8 Astepro Forecast: Revenue ($m), and AGR (%), 2016-2027
Figure 7.9 Patanase Forecast: Revenue($m) and AGR (%), 2016-2027
Figure 7.10 Astelin Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 8.1 The Global Allergic Rhinitis Drugs Market by Region: Revenue ($m), 2016
Figure 8.2 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2016
Figure 8.3 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2021
Figure 8.4 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2027
Figure 8.5 US Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.6 The EU5 Allergic Rhinitis Drugs Market by Country: Revenue ($m), 2016
Figure 8.7 The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2016
Figure 8.8 The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2021
Figure 8.9 The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2027
Figure 8.10 Germany Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.11 UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.12 France Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.13 Italy Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.14 Spain Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.15 China Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.16 Japan Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.17 Russia Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.18 India Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.19 Brazil Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.20 Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 9.1 Leading Companies in The Allergic Rhinitis Drug Market: Revenues ($m), 2016
Figure 9.2 ALK-Abelló: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 9.3 GlaxoSmithKline Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 9.4 Johnson & Johnson Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 9.5 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 9.6 Merck & Co: Allergic Rhinitis Drugs Revenue Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 9.7 Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 9.8 Stallergenes Greer: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 9.9 UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 11.1 Porter’s Five Forces Analysis of the Allergic Rhinitis Drugs Market, 2017

【レポートのキーワード】

アレルギー性鼻炎薬

★調査レポート[アレルギー性鼻炎治療薬の世界市場] ( Global Allergic Rhinitis Drugs Market 2017-2027 / VGAIN7081174) 販売に関する免責事項
[アレルギー性鼻炎治療薬の世界市場] ( Global Allergic Rhinitis Drugs Market 2017-2027 / VGAIN7081174) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆